Aimmune Therapeutics to Participate in Three Investor Conferences in September

BRISBANE, Calif.–(BUSINESS WIRE)– Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that members of the Aimmune executive management team will be
presenting at three upcoming investor conferences in September.

Event: BioCentury NewsMakers in the Biotech Industry
Date:
Friday, September 8, 2017
Time: 11:00 a.m. Eastern Time
Location:
New York
Presenter: CFO Eric Bjerkholt

Event: Bank of America Merrill Lynch Global Healthcare Conference
Date:
Friday, September 15, 2017
Time: 10:40 a.m. British Summer
Time
Location: London
Presenter: CEO Stephen
Dilly, M.B.B.S., Ph.D.

Event: Cantor Fitzgerald Global Healthcare Conference
Date:
Tuesday, September 26, 2017
Time: 9:10 a.m. Eastern Time
Location:
New York
Presenter: CFO Eric Bjerkholt

Live webcasts of the presentations will be accessible on the Events page
under the Investor Relations section of the Aimmune website at www.aimmune.com.
Replays of the webcasts will be available for at least 30 days following
each webcast.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to achieve meaningful levels of protection by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational biologic product using CODIT™, AR101 for
the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials. For more information, please see www.aimmune.com.

This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170906005590/en/